One-year results of excimer laser in situ keratomileusis for hyperopia
Received 19 October 2008; received in revised form 1 March 2009; accepted 3 March 2009.
Purpose
To evaluate the visual and refractive results of hyperopic LASIK.
Setting
Clínica Baviera Instituto Oftalmológico Europeo, Madrid, Spain
Methods
This retrospective consecutive noncomparative observational study evaluated hyperopic LASIK results over 1 year. Outcomes included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), cycloplegic refraction, and corneal topography. Surgery was performed using an MEL 80-G excimer laser. Results were analyzed by preoperative spherical equivalent (SE) (Group 1: ≤+3.50 diopters [D]; Group 2: ≥+3.60 D).
Results
The mean UDVA improved from 0.50 ± 0.3 (SD) to 0.90 ± 0.2 in Group 1 and from 0.50 ± 0.3 to 0.80 ± 0.2 in Group 2 and the mean CDVA, from 0.86 ± 0.2 to 0.93 ± 0.1 and from 0.80 ± 0.2 to 0.90 ± 0.2, respectively. The mean cycloplegic SE improved from +2. 5± 0.8 to +0.1 ± 0.5 in Group 1 and from +4.5 ± 0.6 to +0.4 ± 0.6 in Group 2; 70.9% of eyes and 63.3% of eyes, respectively, were within ±0.50 D of emmetropia. Postoperatively, 92.8% of eyes in Group 1 and 87.8% in Group 2 maintained or gained 1 or more lines of CDVA; 1.7% and 4.0%, respectively, lost 2 or more lines. The safety index was 1.1 in both groups and the efficacy index, 1.01 in Group 1 and 0.98 in Group 2. The enhancement rate was 20.0% and 18.4%, respectively.
Conclusion
Excimer laser LASIK was safe and effective for treating hyperopia up to +6.25 D with no further loss of CDVA lines after enhancement.
From Clínica Baviera/Instituto Oftalmológico Europeo (Llovet, Galal, Ortega, Martin, Baviera) and the Hospital Clínico San Carlos (Benitez-del-Castillo), Faculty of Medicine, Complutense University, Madrid, Spain; Research Institute of Ophthalmology (Galal), Cairo, Egypt
Corresponding author: Ahmed Galal, MD, PhD, Clínica Baviera/Instituto Oftalmológico Europeo, Paseo de la Castellana, 20, 28046 Madrid, Spain.
No author has a financial or proprietary interest in any material or method mentioned.
ABSTRACT